A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03007888 |
Recruitment Status :
Completed
First Posted : January 2, 2017
Last Update Posted : November 6, 2019
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Primary Objective:
To compare the pharmacokinetics (PK) of single and multiple doses of IPX203 with Immediate release carbidopa-levodopa (IR CD-LD) in subjects with advanced Parkinson's disease (PD).
Secondary Objectives:
To compare the pharmacodynamics of single and multiple doses of IPX203 with IR CD-LD.
To compare the efficacy of IPX203 with IR CD-LD following multiple doses.
To evaluate the safety of IPX203.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced Parkinson's Disease | Drug: IR CD-LD Drug: ER CD-LD | Phase 2 |
IPX203 is an investigational product containing CD-LD.
IPX203-B16-01 Study Design:
A randomized, open-label, rater-blinded, multicenter, 2-treatment, 2-period, multiple-dose crossover study.
Approximately 30 qualified IR CD-LD-experienced advanced PD subjects will be randomized.
The study duration will be approximately 8 weeks, including the screening period.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 28 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease |
Actual Study Start Date : | November 14, 2016 |
Actual Primary Completion Date : | August 1, 2017 |
Actual Study Completion Date : | August 1, 2017 |

Arm | Intervention/treatment |
---|---|
Sequence 1
Treatment Period 1: ER CD-LD Capsules - 15 days; Washout Period 7-days; Treatment Period 2- IR CD-LD Tablet - 15 days
|
Drug: IR CD-LD
Immediate Release Tablet containing carbidopa-levodopa flexible dosing Drug: ER CD-LD Extended Release capsules containing carbidopa-levodopa flexible dosing
Other Name: IPX203 |
Sequence 2
Treatment Period 1- IR CD-LD Tablet - 15 days; Washout Period 7-days; Treatment Period 2- ER CD-LD Capsules - 15 days
|
Drug: IR CD-LD
Immediate Release Tablet containing carbidopa-levodopa flexible dosing Drug: ER CD-LD Extended Release capsules containing carbidopa-levodopa flexible dosing
Other Name: IPX203 |
- Percentage off time during waking hours [ Time Frame: Last three days collected at the end of each treatment period ]Patient Diary
- Off time and on time hours during in clinic observation [ Time Frame: Days 1 and 15 ]Subject Motor Assessment by site clinician
- MDS-UPDRS Part III [ Time Frame: Days 1 and 15 ]Based on MDS-UPDRS rating scale
- Pharmacokinetics Cmax [ Time Frame: Day 1 and Day 15 of each treatment period. ]
- Pharmacokinetics AUC [ Time Frame: Day 1 and Day 15 of each treatment period. ]
- Safety and Tolerability as measured by the Incidence of Treatment-Emergent Adverse Events [ Time Frame: Screening through end of study, approximately 8 weeks per subject ]
- Columbia Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Screening through end of study, approximately 8 weeks per subject ]This rating scale measures the occurrence of suicidal ideation and behavior events of clinical trial participants.
- Safety and Tolerability as measured by change from baseline in ECGs [ Time Frame: Screening (baseline) through end of study, approximately 8 weeks per subject ]
- Safety and Tolerability as measured by change from baseline in clinical laboratory tests [ Time Frame: Screening (baseline) through end of study, approximately 8 weeks per subject ]
- Safety and Tolerability as measured by change from baseline in vital signs [ Time Frame: Screening (baseline) through end of study, approximately 8 weeks per subject ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Eligibility will be determined at screening and Visit 1 of the study.
Inclusion Criteria:
- Diagnosed with idiopathic PD at age ≥ 40 years who are being chronically treated with stable regimens of CD-LD but experiencing motor complications.
- Hoehn and Yahr Stages 2, 3, or 4
- Montreal Cognitive Assessment (MoCA) score ≥ 24 at Screening Visit in "on" state.
- For the 4 weeks prior to the Screening, the subject experiences daily "wearing-off" episodes with periods of bradykinesia and rigidity and experiences an "off" state upon awakening on most mornings by history.
- Responsive to CD-LD therapy and currently being treated on a stable regimen with CD-LD for at least 4 weeks prior to Visit 1
- Typically experiences an "on" response with the first dose of IR CD-LD of the day (by subject history).
- By history, efficacy of the first morning dose of IR CD-LD lasts less than 4 hours
Exclusion Criteria:
- History of medical conditions or of a prior surgical procedure that would interfere with LD absorption, such as gastrectomy or proximal small-bowel resection.
- Liver enzyme values ≥ 2.5 x the upper limit of normal; or history of severe hepatic impairment.
- History of drug or alcohol abuse within the 12 months prior to Screening.
- Received within 4 weeks of Visit 1 or planning to take during participation in the clinical study: any doses of a controlled-release (CR) LD apart from a single daily bedtime dose or any doses of Rytary, additional CD (eg, Lodosyn) or benserazide (eg, Serazide), or catechol-O-methyl transferase inhibitors (entacapone or tolcapone) or medications containing these inhibitors (Stalevo). Received within 4 weeks of Visit 1 or planning to take during participation in the clinical study: nonselective monoamine oxidase (MAO) inhibitors, apomorphine, or dopaminergic blocking agents including antiemetics.
- History of psychosis within the past 10 years.
- Treatment with any dopamine antagonist antipsychotics for the purposes of psychosis or bipolar disorder within the last 2 years.
- Based on clinical assessment, subject does not adequately comprehend the terminology needed to complete the PD Diary.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03007888
United States, Arkansas | |
Investigator 110 | |
Little Rock, Arkansas, United States, 72205 | |
Site 114 | |
Little Rock, Arkansas, United States, 72205 | |
United States, Florida | |
Investigator 106 | |
Boca Raton, Florida, United States, 33486 | |
Investigator 112 | |
Naples, Florida, United States, 34102 | |
Investigator 113 | |
Port Charlotte, Florida, United States, 33980 | |
Site 108 | |
Tampa, Florida, United States, 33613 | |
United States, Michigan | |
Investigator 101 | |
Farmington Hills, Michigan, United States, 48334 | |
United States, North Carolina | |
Site 103 | |
Durham, North Carolina, United States, 27705 | |
United States, Ohio | |
Investigator 109 | |
Cleveland, Ohio, United States, 44106 | |
United States, Washington | |
Site 115 | |
Kirkland, Washington, United States, 98034 | |
Investigator 104 | |
Spokane, Washington, United States, 99202 |
Study Director: | Impax Study Director | Impax Laboratories, LLC |
Responsible Party: | Impax Laboratories, LLC |
ClinicalTrials.gov Identifier: | NCT03007888 |
Other Study ID Numbers: |
IPX203-B16-01 |
First Posted: | January 2, 2017 Key Record Dates |
Last Update Posted: | November 6, 2019 |
Last Verified: | August 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
IPX203 (carbidopa-levodopa) Extended-Release capsules |
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases |